Sanofi/Regeneron reveals data from positive trials of Dupixent in the treatment of infantile atopic dermatitis

CompilationAspirin

On December 13, Northeast time, Sanofi and Regeneron disclosed the positive data of the Dupixent Phase III trial Liberty Ad Preschool

This disclosure made Sanofi and Regeneron's Dupixent become more and more stable on the road to becoming a super blockbuster drug with sales of tens of billions of dollars

Sanofi stated as early as August 2021 that Dupixent reached all primary and secondary endpoints in clinical trials with 162 patients

In terms of overall disease improvement: In the trial, 28% of patients using Dupixent and corticosteroid combination therapy achieved complete or almost complete skin clearance at the 16th week, compared with only 4% in the placebo group

Pruritus: Compared with baseline, patients in the Dupixent group improved pruritus by an average of 49%, compared with 2% in the placebo group

Safety: Sanofi said that with regard to safety in the trial, relatively older children are as safe as adolescents and adults

Sanofi and Regeneron will use these data to seek the approval of Dupixent children between the ages of 6 months and 5 years

The star Dupixent is rising

Sanofi’s leadership predicted earlier this year that with its strong data in five indications, Dupixent’s peak sales are likely to exceed 10 billion euros

At the same time, Sanofi said that due to the positive data on chronic spontaneous urticaria, prurigo nodularis, eosinophilic esophagitis and atopic dermatitis in infants and young children, the prospects for future label expansion of Dupixent will also be bright

Reference source: Sanofi, Regeneron plot Dupixent filing in young eczema patients, advancing drug's megablockbuster ambitions